Amgen To Webcast Investor Meeting At AAAAI Virtual Annual Meeting

Rhea-AI Summary

Amgen will host a webcast for investors on February 26, 2021, at 1:00 p.m. ET, during the 2021 American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting. The call will feature David M. Reese, M.D., discussing the tezepelumab Phase 3 NAVIGATOR study results for severe asthma patients, alongside clinical trial investigators. The live audio will be accessible via Amgen's website, with an archive available for 90 days post-event. Amgen focuses on innovative therapeutics and addressing significant medical needs.

THOUSAND OAKS, Calif., Feb. 22, 2021 /PRNewswire/ -- Amgen (NASDAQ:AMGN) will host a webcast call for the investment community in conjunction with the 2021 American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting on Friday, Feb. 26, at 1:00 p.m. ET. David M. Reese, M.D., executive vice president of Research and Development at Amgen, along with clinical trial investigators, will discuss the results of the tezepelumab Phase 3 NAVIGATOR study in patients with severe asthma.

Live audio of the conference call will be broadcast over the internet simultaneously and will be available to members of the news media, investors and the general public.

The webcast, as with other selected presentations regarding developments in Amgen's business given at certain investor and medical conferences, can be accessed on Amgen's website, www.amgen.com, under Investors. Information regarding presentation times, webcast availability and webcast links are noted on Amgen's Investor Relations Events Calendar. The webcast will be archived and available for replay for at least 90 days after the event.

About Amgen 
Amgen is committed to unlocking the potential of biology for patients suffering from serious illnesses by discovering, developing, manufacturing and delivering innovative human therapeutics. This approach begins by using tools like advanced human genetics to unravel the complexities of disease and understand the fundamentals of human biology.  

Amgen focuses on areas of high unmet medical need and leverages its expertise to strive for solutions that improve health outcomes and dramatically improve people's lives. A biotechnology pioneer since 1980, Amgen has grown to be one of the world's leading independent biotechnology companies, has reached millions of patients around the world and is developing a pipeline of medicines with breakaway potential.  

For more information, visit www.amgen.com and follow us on www.twitter.com/amgen.  

CONTACT: Amgen, Thousand Oaks 
Megan Fox, 805-447-1423 (media)
Trish Rowland, 805-447-5631(media) 
Arvind Sood, 805-447-1060 (investors) 

 

View original content to download multimedia:http://www.prnewswire.com/news-releases/amgen-to-webcast-investor-meeting-at-aaaai-virtual-annual-meeting-301232764.html

SOURCE Amgen

FAQ

What is Amgen's webcast about on February 26, 2021?

Amgen's webcast on February 26, 2021, will discuss the results of the tezepelumab Phase 3 NAVIGATOR study in severe asthma.

Who will speak during Amgen's February 26, 2021 webcast?

David M. Reese, M.D., along with clinical trial investigators, will speak during the webcast.

How can I access Amgen's webcast on February 26, 2021?

The webcast can be accessed on Amgen's website under the Investors section.

Will Amgen's February 26, 2021 webcast be available later?

Yes, the webcast will be archived and available for replay for at least 90 days after the event.

What is the focus of Amgen's research and development?

Amgen focuses on developing innovative human therapeutics for serious illnesses, targeting areas of high unmet medical need.